Amphastar Pharmaceuticals (AMPH) Downgraded by Zacks Investment Research to Strong Sell

Amphastar Pharmaceuticals stock has undergone multiple analysts rating changes in the recent past.  Amphastar Pharmaceuticals Downgraded by Zacks Investment Research on 10/11/2021. In a note to investors, the firm issued a new rating of Strong Sell. The analysts previously had rating of Hold.

Shares of Amphastar Pharmaceuticals traded down -$0.03 on Monday, reaching $19.43. 85964 shares of the stock traded hands, compared to its average volume of 157927. Shares of Amphastar Pharmaceuticals were trading at $19.43 on Monday. The firm’s 50 day moving average is $19.19 and its 200 day moving average is $19.04.Amphastar Pharmaceuticals has a 12 month low of $19.40 and a 12 month high of $21.63. While on yearly highs and lows, Amphastar Pharmaceuticals’s today has traded high as $19.76 and has touched $19.40 on the downward trend. See More Analyst Rating at: RATING

Amphastar Pharmaceuticals Earnings and What to expect: 

Amphastar Pharmaceuticals last posted its quarterly earnings results on August 8th, 2021. The reported $0.21 EPS for the quarter, hitting analysts’ consensus estimates of $0.21. The company earned $101.66 million during the quarter, compared to the consensus estimate of $101.38 million. Amphastar Pharmaceuticals has generated $0.64 earnings per share over the last year ($0.21 diluted earnings per share) and currently has a price-to-earnings ratio of 92.5. Earnings for Amphastar Pharmaceuticals are expected to grow by 59.49% in the coming year, from $0.79 to $1.26 per share. Amphastar Pharmaceuticals has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Friday, November 5th, 2021 based off prior year’s report dates.

Earnings for Amphastar Pharmaceuticals are expected to grow by 59.49% in the coming year, from $0.79 to $1.26 per share. The P/E ratio of Amphastar Pharmaceuticals is 92.53, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 14.62. The P/E ratio of Amphastar Pharmaceuticals is 92.53, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 32.34. Amphastar Pharmaceuticals has a P/B Ratio of 2.06. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Amphastar Pharmaceuticals (AMPH) Moving Average Technical Analysis

5 day Moving Average is $19.23 And 5 day price change is $0.33 (1.73%)  with average volume for 5 day average is 126,360. While technical analysis for average 20 days shows significant difference, 20 day moving average is  $18.81 and 20 day price change is $0.98 (5.31%) and average 20 day moving volume is 146,300. 50 day moving average is $19.19  and 50 day price change is -$1.52 ( -7.26%)  and with average volume for 50 days is : 157,430. 200 day moving average is $19.04  and 200 day price change is $0.55 (2.91%)  and with average volume for 200 days is : 194,248.

Other owners latest trading in Amphastar Pharmaceuticals :

  • On 10/7/2021 shares held by State of Alaska Department of Revenue were 26,978 which equates to market value of $0.51M and appx 0.00% owners of Amphastar Pharmaceuticals
  • On 9/3/2021 shares held by Parametric Portfolio Associates LLC were 152,030 which equates to market value of $3.07M and appx 0.00% owners of Amphastar Pharmaceuticals
  • On 8/26/2021 shares held by Comerica Bank were 32,650 which equates to market value of $0.61M and appx 0.00% owners of Amphastar Pharmaceuticals
  • In total Institutional ownership equates to Institutional Ownership Percentage: 56.53% for Amphastar Pharmaceuticals

See More Analyst Rating at: RATING